SJYC07 protocol

SJYC07 is a risk-adapted treatment protocol developed by St. Jude Children's Research Hospital for young children (typically under 3 or 5 years old) with newly diagnosed central nervous system (CNS) tumors, including medulloblastoma, ependymoma, and high-grade glioma. The regimen utilizes a multi-phase approach consisting of induction, consolidation, and maintenance chemotherapy. A key feature of the protocol is the use of high-dose intravenous methotrexate to delay or reduce the need for craniospinal irradiation, thereby minimizing neurocognitive toxicities in the developing brains of infants and toddlers. The protocol stratifies patients into low, intermediate, and high-risk groups; the low-risk arm specifically employs intensive chemotherapy (including cisplatin, cyclophosphamide, and etoposide) to maintain therapeutic efficacy while avoiding the long-term side effects associated with early radiation therapy.

Other names

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or EpendymomaLow-Risk Therapy-St. Jude Children's Research Hospital-central nervous system tumor-medulloblastoma-supratentorial primitive neuroectodermal tumor-pineoblastoma-atypical teratoid rhabdoid tumor-choroid plexus carcinoma-high grade glioma-ependymoma